Intervention Serology and Interaction Substitution: Modeling the Role of 'Shield Immunity' in Reducing COVID-19 Epidemic Spread.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
03 Apr 2020
03 Apr 2020
Historique:
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
The COVID-19 pandemic has precipitated a global crisis, with more than 690,000 confirmed cases and more than 33,000 confirmed deaths globally as of March 30, 2020 [1-4]. At present two central public health control strategies have emerged: mitigation and suppression (e.g, [5]). Both strategies focus on reducing new infections by reducing interactions (and both raise questions of sustainability and long-term tactics). Complementary to those approaches, here we develop and analyze an epidemiological intervention model that leverages serological tests [6, 7] to identify and deploy recovered individuals as focal points for sustaining safer interactions via interaction substitution, i.e., to develop what we term 'shield immunity' at the population scale. Recovered individuals, in the present context, represent those who have developed protective, antibodies to SARS-CoV-2 and are no longer shedding virus [8]. The objective of a shield immunity strategy is to help sustain the interactions necessary for the functioning of essential goods and services (including but not limited to tending to the elderly [9], hospital care, schools, and food supply) while decreasing the probability of transmission during such essential interactions. We show that a shield immunity approach may significantly reduce the length and reduce the overall burden of an outbreak, and can work synergistically with social distancing. The present model highlights the value of serological testing as part of intervention strategies, in addition to its well recognized roles in estimating prevalence [10, 11] and in the potential development of plasma-based therapies [12-15].
Identifiants
pubmed: 32511605
doi: 10.1101/2020.04.01.20049767
pmc: PMC7276032
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2015-20
pubmed: 16461461
Am J Med. 2020 Mar 19;:
pubmed: 32199813
Science. 2020 May 1;368(6490):493-497
pubmed: 32213647
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21484-9
pubmed: 20018697
N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11157-62
pubmed: 16055564
JAMA. 2020 Mar 23;:
pubmed: 32203977
Eur Respir J. 2020 May 19;:
pubmed: 32430429
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
J Infect. 2013 Aug;67(2):130-40
pubmed: 23583636
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Ann Intern Med. 2020 May 5;172(9):619-620
pubmed: 32160299
Nat Med. 2020 May 12;:
pubmed: 32398876
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
J R Soc Interface. 2007 Oct 22;4(16):879-91
pubmed: 17640863
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
Bull Math Biol. 2020 Apr 8;82(4):52
pubmed: 32270376
JAMA. 2020 Mar 27;:
pubmed: 32219429
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Epidemics. 2020 Jun;31:100392
pubmed: 32446187
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116